Halozyme Therapeutics HALO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's additional paid-in capital?
- Halozyme Therapeutics (HALO) reported additional paid-in capital of $27.39M in Q1 2026.
- How has Halozyme Therapeutics's additional paid-in capital changed year-over-year?
- Halozyme Therapeutics's additional paid-in capital increased by 260.5% year-over-year, from $7.6M to $27.39M.
- What is the long-term trend for Halozyme Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's additional paid-in capital has grown at a -54.6% compound annual growth rate (CAGR), from $625.48M to $12M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.